1. Peter E. Norris

    0 Comments Leave a Comment

    1-13 of 13
    1. Mentioned In 13 Articles

    2. Tomophase and MOSS, S.p.A. Expand OCTIS Technology Throughout Italy with New Distribution Agreement

      Tomophase and MOSS, S.p.A. Expand OCTIS Technology Throughout Italy with New Distribution Agreement
      ...S technology for interventional pulmonology throughout Italy," said Ralph Johnston , President and CEO.  Dr. Peter Norris , Tomophase Executive Chairman commented, "The partnership of Tomophase with Franco Papa and MOSS...
      Read Full Article
    3. Integrated disease diagnosis and treatment system

      Integrated disease diagnosis and treatment system
      Designs, implementations, and techniques for optically measuring a sample and integrated systems that provide CT-scan, optical probing and therapy by electromagnetic radiation treatment (e.g. laser, RF, or microwave). Light at different wavelength bands may be used to detect different absorption features in the sample. Multiple light sources may be used including tunable lasers.
      Read Full Article
    4. Tomophase Announces First Sale of Its OCT Imaging System (OCTIS™) for Research Use to the University of Texas

      Tomophase Announces First Sale of Its OCT Imaging System (OCTIS™) for Research Use to the University of Texas
      ...mples of our tissue imaging results are available at http://www.tomophase.com. For further information: Dr. Peter Norris, CEOTomophase CorporationP: (781) 229-5700E: pnorris@tomophase.com Ralph Johnston, President, CO...
      Read Full Article
    5. Tomophase to Exhibit First In-vivo Cross-sectional Images of Pulmonary Stenting Using Proprietary OCT System

      Tomophase to Exhibit First In-vivo Cross-sectional Images of Pulmonary Stenting Using Proprietary OCT System
      ...e information on Tomophase Corporation can be found at http://www.tomophase.com. For further information: Dr. Peter Norris, CEO Tomophase Corporation 1 North Ave., Burlington, MA 01803 P: (781) 229-5700 x122 E: pnorris@t...
      Read Full Article
    6. Tomophase to Exhibit First Cross-Sectional Images of Human Bronchus Using Proprietary OCT System

      ...hase Corporation can be found on the World Wide Web at http://www.tomophase.com. For further information: Dr. Peter Norris, CEO Tomophase Corporation P: (781) 229-5700 E: pnorris@tompohase.com This release was issued thr...
      Read Full Article
    7. 1-13 of 13
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About Peter E. Norris

    Peter Norris is Chairman and CEO of Tomophase.  Prior to co-founding Tomophase, Dr. Norris was a founder of NZ Applied Technologies (NZAT) which developed and manufactured miniaturized components for advanced, high-speed fiber optic communications systems using its proprietary electro-optic device technology. NZAT was incorporated in 1993 and named one of the fastest growing companies in New England in 1998. NZAT was acquired in 2000 by Corning Inc. Dr. Norris has also served as Vice President - Process Technology at EMCORE Corporation  and as a Principal Member of the Technical Staff at GTE laboratories where his group developed high electron mobility transistors (HEMT), quantum well structures and the highest purity GaAs in the world grown by MOCVD technology. Dr. Norris holds a Ph.D., Master’s and Bachelor’s degrees in Solid State Devices from the Massachusetts Institute of Technology.

  3. Quotes

    1. The partnership of Tomophase with Franco Papa and MOSS is another example of the high level of international interest in the OCTIS platform. With their experience in Interventional Pulmonology, MOSS is an excellent fit for OCTIS and our goal of introducing physicians to the greatly expanded pulmonary imaging capabilities it affords. The placement of OCTIS units in two major pulmonary centers in Italy is a major step forward in meeting this goal.
      In Tomophase and MOSS, S.p.A. Expand OCTIS Technology Throughout Italy with New Distribution Agreement
    2. Our company is committed to providing new, innovative tissue imaging systems to improve the management of pulmonary disease. It is gratifying to see a group such as UTMB, with so much experience in Interventional Pulmonology imaging, choose our OCTIS system.
      In Tomophase Announces First Sale of Its OCT Imaging System (OCTIS™) for Research Use to the University of Texas
    3. Our first 510(k) represents a giant step forward in our development of OCT technology for interventional pulmonology, heretofore a greatly underserved market. We plan to consistently expand our system's capabilities in order to maximize the potential for safe, cost-effective, optical imaging, diagnostics and therapy for the management of pulmonary disease.
      In Tomophase OCTIS(TM) Receives FDA 510(K) Clearance to Market
    4. This award will help Tomophase in its efforts to commercialize OCT for pulmonary applications and indicates HHS recognition of its value in this respect. We hope to be first-to-market with an imaging system that will find acceptance within the interventional pulmonology community.
      In Tomophase Receives Qualifying Therapeutic Discovery Project (QTDP) Award
    5. We are pleased to receive this patent which we believe will increase the flexibility of OCTIS as a new tool in the armamentarium for interventional pulmonologists. Our company is committed to providing new, innovative medical imaging products to improve the diagnosis and treatment of diseases of the lung and airways.
      In Tomophase Receives Seventh Patent: Delivering Light via Optical Waveguide and Multiview Optical Probe Head
    6. Our goal at Tomophase is to use our proprietary optical technology to help clinicians image subsurface pulmonary tissue at a level of resolution currently unavailable, while not exposing the patient to potentially harmful radiation, UV light or contrast agents.
      In Tomophase to Exhibit First In-vivo Cross-sectional Images of Pulmonary Stenting Using Proprietary OCT System